Syndax Pharmaceuticals Stock News

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -1.46% to the previous days close as strong demand from buyers drove the stock to $16.83. Actively observing the price movement in the last trading, the stock closed the session at $17.08, falling within a range of $16.60 Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Stock Seems Like A Good Option Read More »

Charles Schwab Investment Management Inc. increased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 16.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 269,631 shares of the companys stock after purchasing an additional 38,698 shares during the period. Charles Schwab Investment Management Inc.s []

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Equities research analysts at B. Riley boosted their FY2021 earnings estimates for Syndax Pharmaceuticals in a note issued to investors on Wednesday, November 17th. B. Riley analyst J. Walsh now anticipates that the company will post earnings of ($2.11) per share for the year, up from their prior forecast of []

Syndax Pharmaceuticals (NASDAQ:SNDX) released its quarterly earnings data on Monday. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.24, MarketWatch Earnings reports. Syndax Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 6,031.18%. During the same quarter in the previous year, the []

WALTHAM, Mass., Nov. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call Transcript

Wall Street brokerages predict that Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) will announce earnings per share of ($0.64) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Syndax Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.63) and the lowest estimate coming in at ($0.65). Syndax Pharmaceuticals reported []

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou

Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax's

The stock price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) increased by over 14% today. This is why it happened.

WALTHAM, Mass., Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipel